Pharma Journalist -

Liminatus Pharma LLC (“Liminatus”), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp (“Iris”), a publicly traded…
Read More...

iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with…
Read More...

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the…
Read More...

Ferring Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved REBYOTA (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic…
Read More...

argenx SE announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of…
Read More...

Kintara Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of…
Read More...

Aldeyra Therapeutics, Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new…
Read More...

Clinigen Limited has agreed to acquire Drug Safety Navigator Inc. (‘DSN’), a specialist pharmacovigilance service provider based in the US. This acquisition enables Clinigen to add…
Read More...

Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with …
Read More...

Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies…
Read More...